KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Deferred Taxes (2024 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Deferred Taxes for 5 consecutive years, with $9.3 million as the latest value for Q1 2026.

  • For Q1 2026, Deferred Taxes fell 3.41% year-over-year to $9.3 million; the TTM value through Mar 2026 reached -$2.5 million, up 97.41%, while the annual FY2025 figure was -$2.2 million, 97.94% up from the prior year.
  • Deferred Taxes hit $9.3 million in Q1 2026 for Alnylam Pharmaceuticals, up from -$27.2 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at $9.7 million in Q2 2025 and bottomed at -$107.4 million in Q4 2024.
  • Average Deferred Taxes over 3 years is -$11.1 million, with a median of $454000.0 recorded in 2024.
  • Year-over-year, Deferred Taxes surged 3534.36% in 2025 and then dropped 3.41% in 2026.
  • Alnylam Pharmaceuticals' Deferred Taxes stood at -$107.4 million in 2024, then soared by 74.7% to -$27.2 million in 2025, then soared by 134.27% to $9.3 million in 2026.
  • According to Business Quant data, Deferred Taxes over the past three periods came in at $9.3 million, -$27.2 million, and $5.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.